| Dr Ann Catherine Hughes Bass, MD | |
|
5130 82nd St, Lubbock, TX 79424-3024 | |
| (806) 761-0275 | |
| (806) 761-0276 |
| Full Name | Dr Ann Catherine Hughes Bass |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 8 Years |
| Location | 5130 82nd St, Lubbock, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750736443 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | R4983 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Medical Center | Lubbock, TX | Hospital |
| Covenant Medical Center | Lubbock, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Umc Physicians | 9830003631 | 114 |
News Archive
A team of researchers at the University of Nottingham have invented a new class of materials that can be injected by surgeons as a low-viscosity fluid into the body that, using body heat as the only trigger, converts into a tough porous material with mechanical properties that mimic human cancellous bone.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.
In a major move, Kadcyla, a breast cancer drug that could prolong life expectancy and disease free survival among breast cancer patients is to be offered on NHS as a result of a deal between the health service and Pharmaceutical company Roche.
Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.
› Verified 3 days ago
| Entity Name | Lamb Healthcare Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700854288 PECOS PAC ID: 6103738471 Enrollment ID: O20040127000737 |
News Archive
A team of researchers at the University of Nottingham have invented a new class of materials that can be injected by surgeons as a low-viscosity fluid into the body that, using body heat as the only trigger, converts into a tough porous material with mechanical properties that mimic human cancellous bone.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.
In a major move, Kadcyla, a breast cancer drug that could prolong life expectancy and disease free survival among breast cancer patients is to be offered on NHS as a result of a deal between the health service and Pharmaceutical company Roche.
Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.
› Verified 3 days ago
| Entity Name | Umc Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669418547 PECOS PAC ID: 9830003631 Enrollment ID: O20040406001716 |
News Archive
A team of researchers at the University of Nottingham have invented a new class of materials that can be injected by surgeons as a low-viscosity fluid into the body that, using body heat as the only trigger, converts into a tough porous material with mechanical properties that mimic human cancellous bone.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.
In a major move, Kadcyla, a breast cancer drug that could prolong life expectancy and disease free survival among breast cancer patients is to be offered on NHS as a result of a deal between the health service and Pharmaceutical company Roche.
Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.
› Verified 3 days ago
| Entity Name | Covenant Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376598904 PECOS PAC ID: 6901889393 Enrollment ID: O20040608000563 |
News Archive
A team of researchers at the University of Nottingham have invented a new class of materials that can be injected by surgeons as a low-viscosity fluid into the body that, using body heat as the only trigger, converts into a tough porous material with mechanical properties that mimic human cancellous bone.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.
In a major move, Kadcyla, a breast cancer drug that could prolong life expectancy and disease free survival among breast cancer patients is to be offered on NHS as a result of a deal between the health service and Pharmaceutical company Roche.
Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.
› Verified 3 days ago
| Entity Name | Concord Medical Group Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083630610 PECOS PAC ID: 0446296818 Enrollment ID: O20050707000531 |
News Archive
A team of researchers at the University of Nottingham have invented a new class of materials that can be injected by surgeons as a low-viscosity fluid into the body that, using body heat as the only trigger, converts into a tough porous material with mechanical properties that mimic human cancellous bone.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.
In a major move, Kadcyla, a breast cancer drug that could prolong life expectancy and disease free survival among breast cancer patients is to be offered on NHS as a result of a deal between the health service and Pharmaceutical company Roche.
Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.
› Verified 3 days ago
| Entity Name | Concord Medical Group Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750790762 PECOS PAC ID: 7810117223 Enrollment ID: O20141007002567 |
News Archive
A team of researchers at the University of Nottingham have invented a new class of materials that can be injected by surgeons as a low-viscosity fluid into the body that, using body heat as the only trigger, converts into a tough porous material with mechanical properties that mimic human cancellous bone.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.
In a major move, Kadcyla, a breast cancer drug that could prolong life expectancy and disease free survival among breast cancer patients is to be offered on NHS as a result of a deal between the health service and Pharmaceutical company Roche.
Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.
› Verified 3 days ago
| Entity Name | Emergency Staffing Solutions Of West Texas Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033593504 PECOS PAC ID: 7113237868 Enrollment ID: O20151109000839 |
News Archive
A team of researchers at the University of Nottingham have invented a new class of materials that can be injected by surgeons as a low-viscosity fluid into the body that, using body heat as the only trigger, converts into a tough porous material with mechanical properties that mimic human cancellous bone.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.
In a major move, Kadcyla, a breast cancer drug that could prolong life expectancy and disease free survival among breast cancer patients is to be offered on NHS as a result of a deal between the health service and Pharmaceutical company Roche.
Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.
› Verified 3 days ago
| Entity Name | Town Square Emergency Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457890402 PECOS PAC ID: 9931485604 Enrollment ID: O20170412000070 |
News Archive
A team of researchers at the University of Nottingham have invented a new class of materials that can be injected by surgeons as a low-viscosity fluid into the body that, using body heat as the only trigger, converts into a tough porous material with mechanical properties that mimic human cancellous bone.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.
In a major move, Kadcyla, a breast cancer drug that could prolong life expectancy and disease free survival among breast cancer patients is to be offered on NHS as a result of a deal between the health service and Pharmaceutical company Roche.
Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.
› Verified 3 days ago
| Entity Name | Ann Hughes Bass Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396363834 PECOS PAC ID: 1254759285 Enrollment ID: O20200908002405 |
News Archive
A team of researchers at the University of Nottingham have invented a new class of materials that can be injected by surgeons as a low-viscosity fluid into the body that, using body heat as the only trigger, converts into a tough porous material with mechanical properties that mimic human cancellous bone.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.
In a major move, Kadcyla, a breast cancer drug that could prolong life expectancy and disease free survival among breast cancer patients is to be offered on NHS as a result of a deal between the health service and Pharmaceutical company Roche.
Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ann Catherine Hughes Bass, MD 5219 City Bank Pkwy Ste 35, Lubbock, TX 79407-3545 Ph: (806) 761-0344 | Dr Ann Catherine Hughes Bass, MD 5130 82nd St, Lubbock, TX 79424-3024 Ph: (806) 761-0275 |
News Archive
A team of researchers at the University of Nottingham have invented a new class of materials that can be injected by surgeons as a low-viscosity fluid into the body that, using body heat as the only trigger, converts into a tough porous material with mechanical properties that mimic human cancellous bone.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed an agreement with venture capital funded DecImmune Therapeutics of Cambridge, Massachusetts, USA.
In a major move, Kadcyla, a breast cancer drug that could prolong life expectancy and disease free survival among breast cancer patients is to be offered on NHS as a result of a deal between the health service and Pharmaceutical company Roche.
Hybridon today announced it had entered into research collaboration and license agreements with Novartis for the discovery, optimization, development and commercialization of Toll-like receptor 9 (TLR9) drug candidates targeting asthma and allergy based on Hybridon's proprietary immune modulatory oligonucleotide (IMO) technology platform.
› Verified 3 days ago
Charles Hudson, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: Concord Medical Group, 1602 Avenue Q, Lubbock, TX 79401 Phone: 972-829-6613 Fax: 800-611-5029 | |
Dr. Ronald L. Cook, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3502 9th St, Suite 1c143, Lubbock, TX 79430 Phone: 806-743-2757 Fax: 806-743-2563 | |
Dr. Scott W. Dahlbeck, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 602 Indiana Ave, Lubbock, TX 79415 Phone: 806-775-8600 Fax: 806-775-8608 | |
Naticia Mortensen, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5915 82nd St, Lubbock, TX 79424 Phone: 806-794-3000 Fax: 806-698-0847 | |
Ryan Daniel Lurtsema, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3601 4th Street Mail Stop 9901, Lubbock, TX 79430 Phone: 806-743-2757 Fax: 806-743-1180 | |
Dr. Cherrylene A Lindgren, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4105 I-27, Lubbock, TX 79404 Phone: 806-762-2633 Fax: 806-761-0431 | |
Jared Zachary Brinker, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4515 Marsha Sharp Fwy, Lubbock, TX 79407 Phone: 806-744-7223 Fax: 806-740-3325 |